News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Lin Shao-Lee
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/06/2023 |
4
| Lin Shao-Lee (CEO) has filed a Form 4 on ACELYRIN, Inc.|
Txns:
| Disposed of 1,161,747 shares
@ $0
Acquired 132,236 shares
@ $0 |
|
| 08/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/19/2023 |
4
| Lin Shao-Lee (Director) has filed a Form 4 on Surrozen, Inc./DE|
Txns:
| Granted 20,000 options to buy
@ $0.56, valued at
$11.2k
|
|
| 05/11/2023 |
4
| Lin Shao-Lee (CEO) has filed a Form 4 on ACELYRIN, Inc.|
Txns:
| Converted 1,161,747 shares
@ $0
Disposed of 1,107,213 shares
@ $0
Acquired 1,107,213 shares
@ $0
Paid exercise price by delivering 337,179 shares
@ $24.69, valued at
$8.3M
Disposed of 677,813 shares
@ $0
Acquired 677,813 shares
@ $0
Disposed of 354,969 shares
@ $0
Acquired 354,969 shares
@ $0
Disposed of 354,969 shares
@ $0
Acquired 354,969 shares
@ $0
Disposed of 349,898 shares
@ $0 |
|
| 05/04/2023 |
4
| Lin Shao-Lee (CEO) has filed a Form 4 on ACELYRIN, Inc.|
Txns:
| Granted 774,788 options to buy
@ $18, valued at
$13.9M
|
|
| 05/04/2023 |
3
| Lin Shao-Lee (CEO) has filed a Form 3 on ACELYRIN, Inc. |
| 10/27/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/14/2022 |
3
| Lin Shao-Lee (Director) has filed a Form 3 on Third Harmonic Bio, Inc. |
| 06/09/2022 |
4
| Lin Shao-Lee (Director) has filed a Form 4 on Surrozen, Inc./DE|
Txns:
| Granted 20,000 options to buy
@ $2.79, valued at
$55.8k
|
|
| 08/16/2021 |
3
| Lin Shao-Lee (Director) has filed a Form 3 on Surrozen, Inc./DE |
| 09/28/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/08/2020 |
4
| Lin Shao-Lee (Director) has filed a Form 4 on Principia Biopharma Inc.|
Txns:
| Granted 10,240 options to buy
@ $62.66, valued at
$641.6k
|
|
| 01/23/2020 |
4
| Lin Shao-Lee (EVP, Head of R&D and CSO) has filed a Form 4 on Horizon Therapeutics Public Ltd Co|
Txns:
| Granted 6,129 shares
@ $0
Paid exercise price by delivering 2,716 shares
@ $38.25, valued at
$103.9k
Granted 12,262 options to buy
@ $0 |
|
| 01/07/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/11/2019 |
4
| Lin Shao-Lee (Director) has filed a Form 4 on Principia Biopharma Inc.|
Txns:
| Granted 10,240 options to buy
@ $31.77, valued at
$325.3k
|
|
| 04/18/2019 |
4
| Lin Shao-Lee (Director) has filed a Form 4 on Principia Biopharma Inc.|
Txns:
| Granted 20,475 options to buy
@ $27.81, valued at
$569.4k
|
|
| 04/18/2019 |
3
| Lin Shao-Lee (Director) has filed a Form 3 on Principia Biopharma Inc. |
| 02/22/2019 |
4
| Lin Shao-Lee (EVP, Head of R&D and CSO) has filed a Form 4 on Horizon Pharma plc|
Txns:
| Granted 35,652 shares
@ $0
Paid exercise price by delivering 15,795 shares
@ $21.54, valued at
$340.2k
|
|
| 01/08/2019 |
4
| Lin Shao-Lee (EVP, Head of R&D and CSO) has filed a Form 4 on Horizon Pharma plc|
Txns:
| Paid exercise price by delivering 8,242 shares
@ $20.39, valued at
$168.1k
Paid exercise price by delivering 14,337 shares
@ $20.39, valued at
$292.3k
Exercised 17,891 restricted stock units
@ $0
Granted 53,948 restricted stock units
@ $0
Exercised 32,362 restricted stock units
@ $0 |
|
| 05/07/2018 |
4
| Lin Shao-Lee (EVP, Head of R&D and CSO) has filed a Form 4 on Horizon Pharma plc|
Txns:
| Granted 97,087 restricted stock units
@ $0 |
|
| 01/05/2018 |
4
| Lin Shao-Lee (EVP, Head of R&D and CSO) has filed a Form 4 on Horizon Pharma plc|
Txns:
| Granted 146,685 options to buy
@ $15.37, valued at
$2.3M
Granted 71,567 restricted stock units
@ $0 |
|
| 01/05/2018 |
3
| Lin Shao-Lee (EVP, Head of R&D and CSO) has filed a Form 3 on Horizon Pharma plc |
|
|